key: cord-0798171-jf9mehf4
authors: Copur, Sidar; Kanbay, Asiye; Kanbay, Mehmet
title: Should we continue to use renin-angiotensin-aldosterone system blockers in patients with COVID-19?
date: 2022-01-06
journal: Clin Kidney J
DOI: 10.1093/ckj/sfac001
sha: 43ab899350919f7314972046acab8d253ef6c337
doc_id: 798171
cord_uid: jf9mehf4

Patients with chronic kidney disease, chronic heart failure and hypertension have an increased risk of COVID-19-related death. Renin-angiotensin-aldosterone system (RAS) blockers are commonly prescribed to decrease morbidity and mortality in these conditions. Following the preclinical demonstration of COVID-19 viral entry into cells via angiotensin converting enzyme-2, use of RAS blockers was questioned in infected individuals. Theodorakopoulou et al. extensively review the pathophysiology behind that hypothesis and observational or clinical trials on RAS blockers and COVID-19. Despite being a scientifically hot spot of an ongoing debate, discontinuation of RAS blockers is not associated with improved clinical outcome in COVID-19 and may have potential harmful effects, including exacerbation of the underlying disease.

This study was not funded by any grant.

MK is a member of the CKJ editorial board. All other authors declare that they have no conflict of interest.

This article does not contain any studies with human participants or animals 

Reninangiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease

Epidemiology and aetiology of heart failure

COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network

Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19

Pathological features of COVID-19 infection from biopsy and autopsy series

A brand-new cardiorenal syndrome in the COVID-19 setting

Acute kidney injury in hospitalized COVID-19 patients

COVID-19 and acute kidney injury

Kidney disease and electrolytes in COVID-19: more than meets the eye

Pathological features of COVID-19 infection from biopsy and autopsy series

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients

Shortterm effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients